Biotek-snakken — November 2023
-
QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan
https://storage.mfn.se/5b1f7126-c0df-4795-b8be-50a98b1a3655/ascelia-pharma-q3-2023-en-231108.pdf
".... Ascelia Pharma to reach headline results from SPARKLE re-evaluation by May 2024 with current funding"
Ascelia Pharma har været min suveræn dårligste investering i 2023. Men håbet lever da endnu, og lad os nu se om ikke de alligevel kommer i mål
-
Penser Access: Intervju med Calliditas Therapeutics- Erik Penser Bank - 8 november 2023:
Penser Access: Intervju med Calliditas Therapeutics- Erik Penser Ba...
I en intervju berättar Renée Aguiar-Lucander, vd på Calliditas, om utvecklingen under det tredje kvartalet. Vi får också veta mer kring marknadsdynamiken i USA och när bolaget förväntar sig...
MFN (mfn.se)
Se intervjun på Erik Penser Banks YouTube-kanal Penser Play: https://youtu.be/h09iFtsdNAo?si=jHZQscPeVZJpXvp5
-
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? https://www.proinvestor.com/investornyt/1077390/the-alzheimers-drug-market-is-heating-up-should-you-buy-the-leading-contenders-stocks
-
Genovis Q3 imorgen d. 14/11.
-
Genovis: Interim Report January-September 2023:
https://mb.cision.com/Main/1712/3875015/2430108.pdf
Genovis ökar omsättning men minskar nettoresultatet - ebitda steg
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind